Cargando…

Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis

BACKGROUND: Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disparities in clinical outcomes after de novo renal transplantation are well documented; whether the efficacy of EVR varies based on recipient ethnicity is unknown. We conducted a comparative risk assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Melancon, Keith, Mulgaonkar, Shamkant P., Delcoro, Carlos, Wiland, Anne, McCague, Kevin, Shihab, Fuad S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888463/
https://www.ncbi.nlm.nih.gov/pubmed/24345868
http://dx.doi.org/10.1097/TP.0b013e3182a486f5
_version_ 1782299063278895104
author Melancon, Keith
Mulgaonkar, Shamkant P.
Delcoro, Carlos
Wiland, Anne
McCague, Kevin
Shihab, Fuad S.
author_facet Melancon, Keith
Mulgaonkar, Shamkant P.
Delcoro, Carlos
Wiland, Anne
McCague, Kevin
Shihab, Fuad S.
author_sort Melancon, Keith
collection PubMed
description BACKGROUND: Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disparities in clinical outcomes after de novo renal transplantation are well documented; whether the efficacy of EVR varies based on recipient ethnicity is unknown. We conducted a comparative risk assessment of EVR by ethnicity. METHODS: Data on 2004 renal transplant recipients from three EVR studies were pooled to identify the impact of ethnicity on efficacy outcomes across EVR dosing groups and control groups. Ethnic groups compared were African Americans, non-U.S. blacks, Asians, Hispanics, and Caucasians. EVR groups received either 1.5 or 3 mg per day, with either standard-dose cyclosporine or reduced-dose cyclosporine. Control groups received mycophenolic acid (MPA) with standard-dose cyclosporine. Composite efficacy failure endpoint was graft loss, death, biopsy-proven acute rejection, or lost to follow-up. Adjusted odds ratios were calculated using a logistic regression model. RESULTS: The proportion of renal transplant recipients who met the composite endpoint was African Americans (46%), non-U.S. black (35%), Caucasian (31%), Hispanic (28%), and Asian (25%). The odds of meeting the composite endpoint were significantly (P=0.0001) greater for African Americans versus Caucasians but did not differ among the other ethnic groups (ethnic groups were only compared with Caucasians). EVR and MPA were associated with similar efficacy among each of the ethnic groups. CONCLUSION: In this pooled data analysis in more than 2000 renal transplant recipients, EVR versus MPA resulted in similar composite endpoint incidence events across ethnicities. Consistent with previously published data, African Americans had poorer clinical outcomes. EVR is efficacious regardless of ethnicity.
format Online
Article
Text
id pubmed-3888463
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-38884632014-01-13 Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis Melancon, Keith Mulgaonkar, Shamkant P. Delcoro, Carlos Wiland, Anne McCague, Kevin Shihab, Fuad S. Transplantation Clinical and Translational Research BACKGROUND: Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disparities in clinical outcomes after de novo renal transplantation are well documented; whether the efficacy of EVR varies based on recipient ethnicity is unknown. We conducted a comparative risk assessment of EVR by ethnicity. METHODS: Data on 2004 renal transplant recipients from three EVR studies were pooled to identify the impact of ethnicity on efficacy outcomes across EVR dosing groups and control groups. Ethnic groups compared were African Americans, non-U.S. blacks, Asians, Hispanics, and Caucasians. EVR groups received either 1.5 or 3 mg per day, with either standard-dose cyclosporine or reduced-dose cyclosporine. Control groups received mycophenolic acid (MPA) with standard-dose cyclosporine. Composite efficacy failure endpoint was graft loss, death, biopsy-proven acute rejection, or lost to follow-up. Adjusted odds ratios were calculated using a logistic regression model. RESULTS: The proportion of renal transplant recipients who met the composite endpoint was African Americans (46%), non-U.S. black (35%), Caucasian (31%), Hispanic (28%), and Asian (25%). The odds of meeting the composite endpoint were significantly (P=0.0001) greater for African Americans versus Caucasians but did not differ among the other ethnic groups (ethnic groups were only compared with Caucasians). EVR and MPA were associated with similar efficacy among each of the ethnic groups. CONCLUSION: In this pooled data analysis in more than 2000 renal transplant recipients, EVR versus MPA resulted in similar composite endpoint incidence events across ethnicities. Consistent with previously published data, African Americans had poorer clinical outcomes. EVR is efficacious regardless of ethnicity. Lippincott Williams & Wilkins 2013-12-27 2013-12-17 /pmc/articles/PMC3888463/ /pubmed/24345868 http://dx.doi.org/10.1097/TP.0b013e3182a486f5 Text en Copyright © 2013 by Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Clinical and Translational Research
Melancon, Keith
Mulgaonkar, Shamkant P.
Delcoro, Carlos
Wiland, Anne
McCague, Kevin
Shihab, Fuad S.
Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis
title Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis
title_full Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis
title_fullStr Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis
title_full_unstemmed Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis
title_short Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis
title_sort outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate: comparative risk assessment results from a pooled analysis
topic Clinical and Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888463/
https://www.ncbi.nlm.nih.gov/pubmed/24345868
http://dx.doi.org/10.1097/TP.0b013e3182a486f5
work_keys_str_mv AT melanconkeith outcomesinethnicminorityrenaltransplantrecipientsreceivingeverolimusversusmycophenolatecomparativeriskassessmentresultsfromapooledanalysis
AT mulgaonkarshamkantp outcomesinethnicminorityrenaltransplantrecipientsreceivingeverolimusversusmycophenolatecomparativeriskassessmentresultsfromapooledanalysis
AT delcorocarlos outcomesinethnicminorityrenaltransplantrecipientsreceivingeverolimusversusmycophenolatecomparativeriskassessmentresultsfromapooledanalysis
AT wilandanne outcomesinethnicminorityrenaltransplantrecipientsreceivingeverolimusversusmycophenolatecomparativeriskassessmentresultsfromapooledanalysis
AT mccaguekevin outcomesinethnicminorityrenaltransplantrecipientsreceivingeverolimusversusmycophenolatecomparativeriskassessmentresultsfromapooledanalysis
AT shihabfuads outcomesinethnicminorityrenaltransplantrecipientsreceivingeverolimusversusmycophenolatecomparativeriskassessmentresultsfromapooledanalysis